Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial

Lisdexamfetamine dimesylate (LDX) is a long-acting, prodrug stimulant therapy for patients with attention-deficit/hyperactivity disorder (ADHD). This randomized placebo-controlled trial of an optimized daily dose of LDX (30, 50 or 70 mg) was conducted in children and adolescents (aged 6–17 years) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Coghill, David R., Banaschewski, Tobias, Lecendreux, Michel, Zuddas, Alessandro, Dittmann, Ralf W., Otero, Isabel Hernández, Civil, Richard, Bloomfield, Ralph, Squires, Liza A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2013
Materias:
Original Contribution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918120/
https://www.ncbi.nlm.nih.gov/pubmed/23708466
http://dx.doi.org/10.1007/s00787-013-0421-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918120/
https://www.ncbi.nlm.nih.gov/pubmed/23708466
http://dx.doi.org/10.1007/s00787-013-0421-y

Ejemplares similares